Markets:

Overview

News

Currencies

International

Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

98.39 -1.21 (-1.21%)

Streaming Delayed Price Updated: 11:04 AM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Here's Why Mirum Pharmaceuticals Stock Is Getting Hammered ↗

August 10, 2022

Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares are trading lower by 13.46% to $23.79 Wednesday afternoon after the company priced its common stock offering of 3.478 million shares at $23 per share....

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Mirum Pharmaceuticals Announces Pricing of Public Offering of Common Stock

August 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Recap: Mirum Pharmaceuticals Q2 Earnings ↗

August 04, 2022

Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Expert Ratings for Mirum Pharmaceuticals ↗

May 23, 2022

Within the last quarter, Mirum Pharmaceuticals (NASDAQ:MIRM) has observed the following analyst ratings:

Via Benzinga

Mirum Pharma Acquires Its Licensing Partner In Cash and Stock ↗

May 23, 2022

Via Benzinga

Recap: Mirum Pharmaceuticals Q1 Earnings ↗

May 05, 2022

Mirum Pharmaceuticals (NASDAQ:MIRM) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock

August 09, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

August 04, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022

July 28, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 08, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Highlights Data Demonstrating Impact of LIVMARLI® (maralixibat) on Patients with Alagille Syndrome at European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting

June 24, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Presents New Data at The International Liver Congress™ of the European Association for the Study of the Liver (EASL)

June 24, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Showcase LIVMARLI® (maralixibat) Data at EASL and ESPGHAN Annual Congresses

June 13, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 10, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

June 06, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

May 25, 2022

Gainers

Via Benzinga

Mirum Pharmaceuticals Acquires Satiogen Pharmaceuticals

May 23, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 18, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 10, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 05, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

A Preview Of Mirum Pharmaceuticals's Earnings ↗

May 04, 2022

Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Mirum...

Via Benzinga

83 Biggest Movers From Yesterday ↗

May 06, 2022

Gainers Hudson Technologies, Inc. (NASDAQ: HDSN) shares jumped 26.9% to close at $9.06 on Thursday after the company reported better-than-expected Q1 EPS and sales results.

Via Benzinga

57 Stocks Moving In Thursday's Mid-Day Session ↗

May 05, 2022

Gainers

Via Benzinga

Mirum Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022

May 02, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 08, 2022

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

The Daily Biotech Pulse: Pfizer Begins Late-Stage Pediatric COVID Pill Study, Midatech And J&J Unit Expand R&D Collaboration, AbbVie-Alvotech Settle Humira Dispute ↗

March 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc...

Via Benzinga

Earnings Scheduled For March 9, 2022 ↗

March 09, 2022

Companies Reporting Before The Bell • REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million. • Express (...

Via Benzinga

Earnings Preview For Mirum Pharmaceuticals ↗

March 08, 2022

Mirum Pharmaceuticals (NASDAQ:MIRM) is set to give its latest quarterly earnings report on Wednesday, 2022-03-09. Here's what investors need to know before the announcement....

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

All News about Mirum Pharmaceuticals, Inc. - common stock

Resources